Know Labs Demonstrates Accuracy of Non-Invasive, Bio-RFID Technology with Proof-of-Principle Study

Know Labs, an emerging developer of non-invasive medical diagnostic technology, announced the results of a proof-of-principle study titled, “Detecting Unique Analyte-Specific Radio Frequency Spectral Responses in Liquid Solutions – Implications for Non-Invasive Physiologic Monitoring,” conducted in collaboration with Mayo Clinic. Know Labs will present the results of the study at the American Physiological Society (APS) Summit, which is being held on April 20-23 in Long Beach, California.

The study demonstrates the accuracy of Know Labs’ proprietary Bio-RFID sensor in quantifying different analytes in vitro, proving a 100% accuracy rate in these tests. The full study is currently undergoing the peer-review publishing process.

Know Labs’ technology platform, Bio-RFID, uses electromagnetic energy in the form of radio waves to non-invasively capture molecular signatures, which can be converted into physiologically meaningful information and insights. While the technology is proven to accurately measure several analytes inside and outside the body, the first application of this technology is aimed at non-invasive glucose monitoring.

Conducted at Mayo Clinic in Rochester, MN in March of 2021, the study included five experiments designed to demonstrate the ability of the Bio-RFID sensor to non-invasively quantify concentrations of solutions using a randomized double-blind trial design, as proxies for biochemical solutions. Solutions including water in isopropyl alcohol, sodium chloride in water, and commercial bleach in water were tested. Data were collected using the Bio-RFID sensor, which generates radio frequency signals and measures received power through an antenna array. The sensor sweeps across the 1500 Megahertz (MHz) - 3000 MHz range at 0.2 MHz intervals, collecting values at 7501 frequencies.